Crescent Biopharma, INC. (CBIO) — SEC Filings

Q: What are the key financial highlights for Crescent Biopharma, INC.?

Key financial highlights for Crescent Biopharma, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Crescent Biopharma, INC.?

Key executives at Crescent Biopharma, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Crescent Biopharma, INC. stock?

Risk factors for Crescent Biopharma, INC. (CBIO) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Crescent Biopharma, INC.?

Forward-looking statements and predictions from Crescent Biopharma, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Crescent Biopharma, INC.. Recent 8-K filing on Dec 4, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Crescent Biopharma, INC. on SEC EDGAR

Overview

Crescent Biopharma, INC. (CBIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Crescent Biopharma, Inc. (CBIO) reported a significant increase in cash and cash equivalents to $133.265 million as of September 30, 2025, up from $34.766 million at December 31, 2024, primarily due to a Pre-Closing Financing that generated $143.027 million. The company incurred a net loss of $24.60

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 3 bullish, 3 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Crescent Biopharma, INC. is neutral.

Filing Type Overview

Crescent Biopharma, INC. (CBIO) has filed 20 8-K, 6 10-Q, 2 10-K, 2 SC 13G, 5 SC 13G/A, 1 SC 13D, 3 SC 13D/A, 1 DEF 14A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (40)

8-K Filing — 8-K · Dec 4, 2025
Crescent Biopharma's Cash Surges Post-Financing Amidst Deepening Losses — 10-Q · Nov 6, 2025 Risk: high
Crescent Biopharma, Inc. (CBIO) reported a significant increase in cash and cash equivalents to $133.265 million as of September 30, 2025, up from $34.766 milli
Crescent Biopharma Reports Zero Revenue, $20.1M Net Loss Amid Pipeline Development — 10-Q · Jul 31, 2025 Risk: high
CRESCENT BIOPHARMA, INC. (CBIO) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company incu
GlycoMimetics Reports Material Definitive Agreement & Asset Changes — 8-K · Jun 18, 2025 Risk: medium
GlycoMimetics, Inc. filed an 8-K on June 18, 2025, reporting several material events. These include entry into a material definitive agreement, completion of an
GlycoMimetics Files 8-K: Shareholder Vote, Reg FD, Other Events — 8-K · Jun 6, 2025 Risk: medium
On June 5, 2025, GlycoMimetics, Inc. filed an 8-K report detailing several events. The company announced the submission of matters to a vote of its security hol
GlycoMimetics Files 8-K Report — 8-K · May 30, 2025 Risk: low
On May 30, 2025, GlycoMimetics, Inc. filed an 8-K report. The filing indicates an 'Other Event' and is related to the company's ongoing operations and reporting
GlycoMimetics Q1 2025 10-Q Filed — 10-Q · May 14, 2025 Risk: medium
GlycoMimetics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $64.5 million and total liabilities of $64.4 millio
GlycoMimetics Enters Material Definitive Agreement — 8-K · Apr 29, 2025 Risk: medium
On April 28, 2025, GlycoMimetics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices
GlycoMimetics Reports Agreement Termination & Director Changes — 8-K · Feb 25, 2025 Risk: medium
GlycoMimetics, Inc. reported on February 19, 2025, the termination of a material definitive agreement and changes in its board of directors and officer compensa
GlycoMimetics Enters Material Definitive Agreement — 8-K · Feb 14, 2025 Risk: medium
GlycoMimetics, Inc. announced on February 14, 2025, that it has entered into a Material Definitive Agreement. The company also filed financial statements and ex
GlycoMimetics Files 2024 10-K, Reports $64.4M Cash — 10-K · Feb 13, 2025 Risk: medium
GlycoMimetics Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, based in Rockville, MD, operates in the pharmaceutical preparations
GlycoMimetics Announces Executive and Director Changes — 8-K · Jan 31, 2025 Risk: medium
GlycoMimetics, Inc. announced on January 29, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure of certa
8-K Filing — 8-K · Jan 13, 2025
GlycoMimetics Faces Delisting Concerns — 8-K · Dec 26, 2024 Risk: high
GlycoMimetics, Inc. filed an 8-K on December 26, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of December
SC 13G Filing — SC 13G · Nov 27, 2024
GlycoMimetics Q3 2024 Update: Equity Changes Detailed — 10-Q · Nov 13, 2024 Risk: medium
GlycoMimetics Inc. reported its third quarter 2024 results on November 13, 2024. The company's financial statements for the period ending September 30, 2024, sh
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
Royalty Pharma to Acquire GlycoMimetics for $2.00/Share — 8-K · Nov 7, 2024 Risk: medium
GlycoMimetics, Inc. announced on November 7, 2024, that it has entered into a definitive agreement to be acquired by Royalty Pharma plc for $2.00 per share in c
SC 13G Filing — SC 13G · Nov 6, 2024
Adage Capital Management Files 13D for GlycoMimetics — SC 13D · Nov 4, 2024 Risk: medium
Adage Capital Management, L.P. has filed a Schedule 13D on November 4, 2024, indicating a change in beneficial ownership of GlycoMimetics, Inc. common stock. Th
Royalty Pharma to Acquire GlycoMimetics for $203M — 8-K · Oct 29, 2024 Risk: medium
GlycoMimetics, Inc. announced on October 28, 2024, that it has entered into a definitive agreement to be acquired by Royalty Pharma plc for approximately $4.10
SC 13G/A Filing — SC 13G/A · Aug 15, 2024
GlycoMimetics Q2 2024 Financials: Capital Structure Insights — 10-Q · Aug 8, 2024 Risk: medium
GlycoMimetics Inc. reported its second quarter 2024 financial results on August 8, 2024. The company's financial statements for the period ending June 30, 2024,
Royalty Pharma to Acquire GlycoMimetics for $200M — 8-K · Jul 30, 2024 Risk: medium
GlycoMimetics, Inc. announced on July 24, 2024, that it has entered into a definitive agreement to be acquired by Royalty Pharma plc for $200 million in cash. T
SC 13G/A Filing — SC 13G/A · Jul 29, 2024
GlycoMimetics Faces Delisting Concerns — 8-K · Jun 26, 2024 Risk: high
GlycoMimetics, Inc. filed an 8-K on June 26, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in Rockv
GlycoMimetics Appoints New CMO, CFO, and Director — 8-K · Jun 13, 2024 Risk: medium
GlycoMimetics, Inc. announced on June 10, 2024, changes in its executive and director roles. Dr. Helen B. Foy was appointed as Chief Medical Officer, and Mr. Mi
GlycoMimetics Files 8-K for Financial Statements and Exhibits — 8-K · Jun 4, 2024 Risk: low
On June 4, 2024, GlycoMimetics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures rel
GlycoMimetics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
GLYCOMIMETICS INC (CBIO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. GlycoMimetics Inc. filed a 10-Q report for the period ending March 31, 202
NEA 10 Amends Stake in GlycoMimetics — SC 13D/A · May 8, 2024 Risk: medium
New Enterprise Associates 10, L.P. (NEA 10) filed an amendment (No. 4) to its Schedule 13D on May 8, 2024, regarding its holdings in GlycoMimetics, Inc. The fil
GlycoMimetics Files 8-K on Operations — 8-K · May 6, 2024 Risk: low
GlycoMimetics, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosu
GlycoMimetics Files 8-K on Shareholder Votes and Financials — 8-K · May 2, 2024 Risk: low
GlycoMimetics, Inc. filed an 8-K on May 1, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing does not cont
GlycoMimetics Inc. Announces Annual Meeting of Stockholders on May 1, 2024 — DEF 14A · Apr 1, 2024 Risk: low
GLYCOMIMETICS INC (CBIO) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. Annual Meeting of Stockholders to be held virtually on May 1, 2024, at
GlycoMimetics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 27, 2024 Risk: medium
GLYCOMIMETICS INC (CBIO) filed a Annual Report (10-K) with the SEC on March 27, 2024. GlycoMimetics Inc. filed its 10-K report for the fiscal year ending Decemb
GlycoMimetics Files 8-K for Financials and Exhibits — 8-K · Mar 1, 2024 Risk: low
GlycoMimetics, Inc. filed an 8-K on March 1, 2024, reporting on its financial statements and exhibits. The filing does not contain specific financial figures or
NEA Amends GlycoMimetics Stake, Leadership Noted — SC 13D/A · Feb 29, 2024 Risk: low
New Enterprise Associates (NEA) filed an SC 13D/A Amendment No. 3 for GlycoMimetics, Inc. on February 29, 2024. The filing updates their beneficial ownership of
NEA Amends GlycoMimetics Stake, Signals Ownership Change — SC 13D/A · Feb 12, 2024 Risk: medium
New Enterprise Associates (NEA) 10, L.P. and its affiliated entities, including NEA Partners 13, L.P. and NEA 13 GP, LTD, filed an amendment to their Schedule 1
Artal International S.C.A. Updates GlycoMimetics Stake — SC 13G/A · Feb 9, 2024 Risk: low
Artal International S.C.A. and its affiliated entities, including Artal Group S.A. and Invus Public Equities, L.P., filed an amended SC 13G/A on February 9, 202
Biotechnology Value Fund Amends GLYC Stake, Signals Ownership Change — SC 13G/A · Jan 29, 2024
Biotechnology Value Fund, L.P. (BVF) has filed an Amendment No. 4 to its Schedule 13G, indicating a change in its ownership of GlycoMimetics, Inc. (NASDAQ: GLYC
GlycoMimetics Files 8-K on Material Agreement; Details Pending — 8-K · Jan 2, 2024
GlycoMimetics, Inc. filed an 8-K on January 2, 2024, to report an "Entry into a Material Definitive Agreement." While the filing confirms the event date and the

Risk Profile

Risk Assessment: Of CBIO's 31 recent filings, 4 were flagged as high-risk, 18 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Crescent Biopharma, INC.'s most recent 10-Q filing (Nov 6, 2025):

Revenue: $0
Net Income: -$61.545M
EPS: -$7.89
Debt-to-Equity: 0.18
Cash Position: $133.265M
Operating Margin: N/A
Total Assets: $138.269M
Total Debt: $0

Key Executives

Robert Atchinson
Dr. Helen B. Foy
Mr. Michael J. Yaszemski
Ms. Karen L. King
ANTHONY A. FLORENCE, JR
MOHAMAD H. MAKHZOUMI
SCOTT D. SANDELL
Stephanie Brecher
Anthony A. Florence, Jr.
Mohamad H. Makhzoumi
Scott D. Sandell
Mr. Amaury Wittouck

Industry Context

The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like CBIO operate in a competitive landscape where innovation is key, but success is often dependent on securing substantial funding to advance drug candidates through preclinical and clinical trials. The sector faces intense scrutiny from regulatory bodies like the FDA, and market approval is a critical determinant of commercial viability.

Top Tags

financials (6) · 10-Q (4) · sec-filing (4) · institutional-investor (4) · amendment (4) · material-agreement (3) · acquisition (3) · merger (3) · Biotechnology (2) · Net Loss (2)

Key Numbers

Cash and cash equivalents: $133.265M — Increased from $34.766M at December 31, 2024, providing significant liquidity.
Net loss for nine months ended September 30, 2025: $61.545M — Represents a substantial increase from $2.631M in the prior year period, indicating rising operational costs.
Research and development expenses for nine months ended September 30, 2025: $43.059M — Significantly higher than $2.473M in the prior year, reflecting increased investment in drug development.
Proceeds from Pre-Closing Financing: $143.027M — Primary source of the increase in cash and cash equivalents.
Total liabilities as of September 30, 2025: $21.628M — Decreased from $47.096M at December 31, 2024, largely due to debt conversion.
Convertible note principal and non-cash accrued interest converted to ordinary shares: $40.515M — A key non-cash financing activity that reduced liabilities and increased equity.
Ordinary shares outstanding: 13,892,516 — As of November 3, 2025, reflecting dilution from financing activities.
Total shareholders' equity (deficit): $116.641M — Improved from a deficit of $(15.479)M at December 31, 2024, due to financing activities.
Net loss per ordinary share for three months ended September 30, 2025: $1.27 — Indicates the per-share impact of the company's ongoing losses.
Net loss per ordinary share for nine months ended September 30, 2025: $7.89 — Reflects the cumulative per-share loss over the period.
Revenue: $0 — for the three and six months ended June 30, 2025, indicating pre-commercial stage
Net Loss: $10.5M — for the three months ended June 30, 2025, reflecting ongoing R&D expenses
Total Assets: $15.2M — as of June 30, 2025, a decrease from $25.7M at December 31, 2024
Date of Name Change: 2003-07-11 — when GlycoMimetics Inc. became CRESCENT BIOPHARMA, INC. via reverse recapitalization
Total Liabilities: $64.4B — As of March 31, 2025, representing the company's total obligations.

Forward-Looking Statements

{"claim":"New Enterprise Associates will continue to be a significant shareholder in GlycoMimetics, maintaining influence over strategic decisions.","entity":"New Enterprise Associates 10, L.P.","targetDate":"2025-02-12","confidence":"medium"}

Related Companies

GLYC · GMLX · RPRX

Frequently Asked Questions

What are the latest SEC filings for Crescent Biopharma, INC. (CBIO)?

Crescent Biopharma, INC. has 40 recent SEC filings from Jan 2024 to Dec 2025, including 20 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CBIO filings?

Across 40 filings, the sentiment breakdown is: 3 bullish, 3 bearish, 33 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Crescent Biopharma, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Crescent Biopharma, INC. (CBIO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Crescent Biopharma, INC.?

Key financial highlights from Crescent Biopharma, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CBIO?

The investment thesis for CBIO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Crescent Biopharma, INC.?

Key executives identified across Crescent Biopharma, INC.'s filings include Robert Atchinson, Dr. Helen B. Foy, Mr. Michael J. Yaszemski, Ms. Karen L. King, ANTHONY A. FLORENCE, JR and 7 others.

What are the main risk factors for Crescent Biopharma, INC. stock?

Of CBIO's 31 assessed filings, 4 were flagged high-risk, 18 medium-risk, and 9 low-risk.

What are recent predictions and forward guidance from Crescent Biopharma, INC.?

Recent forward-looking statements from Crescent Biopharma, INC. include guidance on {"claim":"New Enterprise Associates will continue to be a significant shareholder in GlycoMimetics, maintaining influenc.